India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln

Investing.com

10小时前

Investing.com-- Sun Pharmaceutical (TADAWUL:2070) Industries Ltd. (NSE:SUN) said on Monday that it will buy Checkpoint Therapeutics Inc (NASDAQ:CKPT)- a Nasdaq-listed immunotherapy and oncology firm- for about $355 million.

Sun said it will offer $4.10 in cash for each share in Checkpoint, a nearly 66% premium to Checkpoint’s Friday close of $2.470. Checkpoint shareholders will also receive a commitment for an additional $0.70 per share if the company’s cosbelimab treatment is approved in Europe prior to certain deadlines.

Cosibelimab- which is Checkpoint’s FDA-approved treatment for certain variants of skin cancer- is the key motivator behind Sun’s bid, with the Indian pharmaceutical firm stating that the deal will introduce Checkpoint’s treatment across more countries.

The deal is expected to be completed in the second quarter of 2025.

Sun has also entered into a royalty agreement with Fortress Biotech Inc (NASDAQ:FBIO), Checkpoint’s controlling shareholder, under which the latter will receive payments based on future sales of cosibelimab.

Sun Pharma was founded in 1983 and is one of the world’s biggest manufacturers of generic pharmaceuticals, which are also a major export product for India. The company has diversified into a wide range of healthcare services in recent years, and offers services in over 100 countries.

Related Articles

India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln

Trump says government shutdown is possible, but expects to avert it

Seven & i in talks with Couche-Tard over store sales for merger deal

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2518250530"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2518250530\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2518250530?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-10 11:13","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2518250530","market":"us","top_or_hot":-1,"title":"India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln","media":"Investing.com","content":"<html><body><p>Investing.com-- Sun Pharmaceutical (TADAWUL:2070) Industries Ltd. (NSE:SUN) said on Monday that it will buy Checkpoint <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc (NASDAQ:CKPT)- a Nasdaq-listed immunotherapy and oncology firm- for about $355 million. </p>\n<p dir=\"ltr\">Sun said it will offer $4.10 in cash for each share in Checkpoint, a nearly 66% premium to Checkpoint’s Friday close of $2.470. Checkpoint shareholders will also receive a commitment for an additional $0.70 per share if the company’s cosbelimab treatment is approved in Europe prior to certain deadlines. </p>\n<p dir=\"ltr\">Cosibelimab- which is Checkpoint’s FDA-approved treatment for certain variants of skin cancer- is the key motivator behind Sun’s bid, with the Indian pharmaceutical firm stating that the deal will introduce Checkpoint’s treatment across more countries. </p>\n<p dir=\"ltr\">The deal is expected to be completed in the second quarter of 2025. </p>\n<p dir=\"ltr\">Sun has also entered into a royalty agreement with Fortress Biotech Inc (NASDAQ:FBIO), Checkpoint’s controlling shareholder, under which the latter will receive payments based on future sales of cosibelimab. </p>\n<p dir=\"ltr\">Sun Pharma was founded in 1983 and is one of the world’s biggest manufacturers of generic pharmaceuticals, which are also a major export product for India. The company has diversified into a wide range of healthcare services in recent years, and offers services in over 100 countries. </p>\n<p>Related Articles</p>\n<p>India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln</p>\n<p>Trump says government shutdown is possible, but expects to avert it</p>\n<p>Seven & i in talks with Couche-Tard over store sales for merger deal</p>\n</body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndia’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln\n</h2>\n<h4 class=\"meta\">\n\n\n2025-03-10 11:13 GMT+8   <a href=\"https://finance.yahoo.com/news/india-sun-pharma-buy-checkpoint-031303490.html\"><strong>Investing.com</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Investing.com-- Sun Pharmaceutical (TADAWUL:2070) Industries Ltd. (NSE:SUN) said on Monday that it will buy Checkpoint Therapeutics Inc (NASDAQ:CKPT)- a Nasdaq-listed immunotherapy and oncology firm- ...</p>\n<a href=\"https://finance.yahoo.com/news/india-sun-pharma-buy-checkpoint-031303490.html\">网页链接</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"USJW.SI","symbol_name":"ALPHAB 3xLongSG261006","start_time":0,"source_url":"https://finance.yahoo.com/news/india-sun-pharma-buy-checkpoint-031303490.html","article_id":"2518250530","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518250530","pubTimestamp":1741576383,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Investing.com--Sun Pharmaceutical  Industries Ltd.  said on Monday that it will buy Checkpoint Therapeutics Inc - a Nasdaq-listed immunotherapy and oncology firm- for about $355 million.Sun said it will offer $4.10 in cash for each share in Checkpoint, a nearly 66% premium to Checkpoint’s Friday close of $2.470. Checkpoint shareholders will also receive a commitment for an additional $0.70 per share if the company’s cosbelimab treatment is approved in Europe prior to certain deadlines.Cosibelimab- which is Checkpoint’s FDA-approved treatment for certain variants of skin cancer- is the key motivator behind Sun’s bid, with the Indian pharmaceutical firm stating that the deal will introduce Checkpoint’s treatment across more countries.The deal is expected to be completed in the second quarter of 2025.Sun has also entered into a royalty agreement with Fortress Biotech Inc , Checkpoint’s controlling shareholder, under which the latter will receive payments based on future sales of cosibelim","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"USJW.SI":"ALPHAB 3xLongSG261006","LENZ":"Therapeutics","NVIW.SI":"NVDA 3xLongSG261006",".IXIC":"NASDAQ Composite","CKPT":"Checkpoint Therapeutics, Inc.","SQQQ":"纳指三倍做空ETF","FBIO":"Fortress Biotech Inc.","PSQ":"纳指反向ETF","BK4139":"生物科技","USAW.SI":"AMZN 3xLongSG261006","QID":"纳指两倍做空ETF","TSYW.SI":"TESLA 3xLongSG261006","QLD":"纳指两倍做多ETF","TQQQ":"纳指三倍做多ETF"},"translate_title":"印度Sun Pharma将以3.55亿美元收购Checkpoint Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FBIO":1,"LENZ":1,"CKPT":0.9,".IXIC":0.72,"MNQmain":0.6,"NQmain":0.6,"NVIW.SI":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6,"TSYW.SI":0.6,"USAW.SI":0.6,"USJW.SI":0.6},"content_text":"Investing.com-- Sun Pharmaceutical (TADAWUL:2070) Industries Ltd. (NSE:SUN) said on Monday that it will buy Checkpoint Therapeutics Inc (NASDAQ:CKPT)- a Nasdaq-listed immunotherapy and oncology firm- for about $355 million. \nSun said it will offer $4.10 in cash for each share in Checkpoint, a nearly 66% premium to Checkpoint’s Friday close of $2.470. Checkpoint shareholders will also receive a commitment for an additional $0.70 per share if the company’s cosbelimab treatment is approved in Europe prior to certain deadlines. \nCosibelimab- which is Checkpoint’s FDA-approved treatment for certain variants of skin cancer- is the key motivator behind Sun’s bid, with the Indian pharmaceutical firm stating that the deal will introduce Checkpoint’s treatment across more countries. \nThe deal is expected to be completed in the second quarter of 2025. \nSun has also entered into a royalty agreement with Fortress Biotech Inc (NASDAQ:FBIO), Checkpoint’s controlling shareholder, under which the latter will receive payments based on future sales of cosibelimab. \nSun Pharma was founded in 1983 and is one of the world’s biggest manufacturers of generic pharmaceuticals, which are also a major export product for India. The company has diversified into a wide range of healthcare services in recent years, and offers services in over 100 countries. \nRelated Articles\nIndia’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln\nTrump says government shutdown is possible, but expects to avert it\nSeven & i in talks with Couche-Tard over store sales for merger deal","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0}}}